Literature DB >> 11994439

4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.

Tao Wen1, Jacob Bukczynski, Tania H Watts.   

Abstract

4-1BB (CD137) is a costimulatory member of the TNFR family expressed on activated T cells. Its ligand, 4-1BBL, is expressed on activated APC. In the mouse, CD8 T cells are preferentially activated by agonistic anti-murine 4-1BB Abs. However, murine 4-1BBL can stimulate both CD4 and CD8 T cells. To date, there are only limited data on the effects of 4-1BBL on human T cell responses. To further understand the role of 4-1BBL in human T cell responses, we compared human CD4 and CD8 T cell responses to transfected human 4-1BBL plus TCR-mediated stimulation. Both human CD4 and CD8 T cells responded to 4-1BBL. The presence of 4-1BBL on the APC led to increased expansion, cytokine production, and the development of cytolytic effector function by human T cells. In unfractionated T cell cultures, CD4 and CD8 T cells could expand to a similar extent in response to signals through the TCR and 4-1BB, as measured by CFSE labeling and by quantitating T cell numbers in the cultures. In contrast to the results with total T cells, isolated CD8 T cells produced less IL-2 and expanded to a lesser extent than isolated CD4 T cells responding to 4-1BBL. Thus, 4-1BBL is most effective when both CD4 and CD8 T cells are included in the cultures. CD28 and 4-1BB were found to synergize in the induction of IL-2 by human T cells, and CTLA-Ig partially blocked 4-1BBL-dependent IL-2 production. However, a portion of the 4-1BBL-mediated effects were independent of CD28-B7 interaction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994439     DOI: 10.4049/jimmunol.168.10.4897

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy.

Authors:  Kazue Watanabe; Susumu Suzuki; Michi Kamei; Shingo Toji; Takakazu Kawase; Toshitada Takahashi; Kiyotaka Kuzushima; Yoshiki Akatsuka
Journal:  Int J Hematol       Date:  2008-08-05       Impact factor: 2.490

2.  An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.

Authors:  Yik Andy Yeung; Veena Krishnamoorthy; Danielle Dettling; Cesar Sommer; Kris Poulsen; Irene Ni; Amber Pham; Wei Chen; Sindy Liao-Chan; Kevin Lindquist; S Michael Chin; Allison Given Chunyk; Wenyue Hu; Barbra Sasu; Javier Chaparro-Riggers; Ivana Djuretic
Journal:  Mol Ther       Date:  2020-01-14       Impact factor: 11.454

3.  Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.

Authors:  P Maerten; B S Kwon; C Shen; G De Hertogh; P Cadot; D M A Bullens; L Overbergh; C Mathieu; G Van Assche; K Geboes; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

5.  4-1BB functions as a survival factor in dendritic cells.

Authors:  Beom K Choi; Young H Kim; Patrick M Kwon; Sang C Lee; Sang W Kang; Moon S Kim; Myoung J Lee; Byoung S Kwon
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 6.  Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities.

Authors:  Matthias Wölfl; Jürgen Kuball; Matthias Eyrich; Paul G Schlegel; Philip D Greenberg
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

7.  Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications.

Authors:  Shuhong Han; Yuju Huang; Yin Liang; Yuchin Ho; Yichen Wang; Lung-Ji Chang
Journal:  J Hematol Oncol       Date:  2009-08-06       Impact factor: 17.388

8.  Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.

Authors:  Jennifer A Westwood; Phillip K Darcy; Preethi Mayura Guru; Janelle Sharkey; Hollie J Pegram; Sally M Amos; Mark J Smyth; Michael H Kershaw
Journal:  J Transl Med       Date:  2010-04-28       Impact factor: 5.531

9.  HIV-specific CD8+ T cells from elite controllers are primed for survival.

Authors:  Jiyu Yan; Steffanie Sabbaj; Anju Bansal; Nilesh Amatya; John J Shacka; Paul A Goepfert; Sonya L Heath
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

Authors:  Jing-Hua Huang; Song-Nan Zhang; Kyung-Ju Choi; Il-Kyu Choi; Joo-Hang Kim; Min-Geol Lee; Mingul Lee; Hoguen Kim; Chae-Ok Yun
Journal:  Mol Ther       Date:  2009-09-08       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.